


# Eurofins CDMO

## (Bio)Pharmaceutical Development Services


October, 2019

# Eurofins Overview




**Global leader in the pharmaceutical,  
food, environmental testing market**

- **Founded in 1987 in Nantes, France**
- **HQ : Brussels, Belgium**
- **Listed in Paris**
- **Revenues : € 3.78 Billion (2018)**
- **Network of 800 laboratories in 47 countries**
- **Employees : >45,000**



# Eurofins Biopharma Services



## Discovery Pharmacology

High-throughput screening

Molecular Pharmacology

Cell-based Assays  
*In Vitro* Screening  
*In Vitro* Profiling  
*In Vivo* Safety  
*In Vivo* efficacy



## Pre-Clinical/ Early Development

Pharmacology & Bioanalytical Analysis

DMPK/ADME

Immunogenicity

Biosafety

Toxicology and toxicity



## Genomics

Oligonucleotides

Sequencing

Gene Synthesis

Gene Fragments

Next Generation Sequencing

Plasmid Veriication

GMP & Regulatory Oligo Manufacturing



## Clinical

Biomarkers

Bioanalysis

Immunogenicity

Proteomics

Microbiological and Anti-infective analysis

Bioavailability

Bioequivalence

Phase I/II Studies



## Specialty Clinical Diagnostics

Cardiovascular Diseases

Molecular

Infectious Diseases

Immune Response Monitoring

Vaccine Safety/Efficacy

Allergy & Hypersensitivity  
Biomarkers & companion diagnostics



## BioPharma Product Testing (BPT)

Pharmaceuticals

Biologics

Medical Devices

Safety, Characterization, & Quality Control

Process Development

Starting materials through finished products

Packaging



## CDMO

Complex small molecule API Development

Biologics Drug Substance Development


Cytotoxic & Highly Potent Compounds

Pre-Formulation/ Formulation

Non-GMP & GMP Manufacturing


Fill & Finish

Clinical Trial Material:  
Packaging & Logistics




The most innovative, flexible and agile team of science experts in the global CDMO market.

Fully integrated services enabling the most efficient pathway from preclinical candidate to late phase clinical product and commercialization.




# Services




Oral   Sub Lingual   Topical   Transdermal   Inhalation   Mucosal   Injectable 	INCLUDING HIGHLY POTENT 	DRUG SUBSTANCE		DRUG PRODUCT	
		Development	Manufacturing	Development	Manufacturing
<b>BIOLOGICALS</b>					
<b>SMALL MOLECULES</b>					


# Global Presence



# Why Work with Us?



# Depth of Experience



Small molecule drug development projects

610<sup>+</sup>



Biologic drug development projects

120<sup>+</sup>



Number of Batches Produced


500<sup>+</sup>  
Yearly



Number of active clients

155<sup>+</sup>





## Focused On:

### ▪ **Complex API Synthesis**

- Multi-step, multiple chiral centers
- Synthetic route evaluation & design
- PR&D Scale-up
- Prep Chromatography

### ▪ **Small Volume Niche APIs**

- Niche indications
- Orphan drugs

### ▪ **Highly Potent Compounds**

- Up to Cat 3b in Pilot Plants
- Up to Cat 4 in dedicated R&D & GMP Facility

## To Support:


### ▪ **IND Development Programs**

- Preclinical to Phase II


### ▪ **Phase II to Commercialization**


### ▪ **Registration and Validation**

**“The Right Development at the Right Time”**





# API | Technology Dev. & Manufacturing





- **Route Scouting**
- **Process Evaluation**
- **Scale-up Development**
- **Design of Experiments (DoE)**
- **Critical Process Parameter**
- **Impurity Marker Synthesis**
- **Impurity Fate and Purge Studies**
- **Structure Characterization & Elucidation**
- **Automated Flash Chromatography (mg to kg)**
- **Polymorph Screening**
- **Solid State Science**
- **Validation Preparation**
- **Process Hazards Safety Assessment**



## ▪ Spray Drying

- Continuous Process
- Amorphous Dispersions of API

## ▪ Flow Chemistry

- Hazardous Reactions
- Rapid Reaction Optimization
- Ideal for Reaction Condition and Scale Up



Spray Drying

## ▪ Freez-Drying

- Labile and/or Ionized Compounds
- Oligopeptides and Oligonucleotides

## ▪ Parallel Reactors

- Process Optimization and DoE Studies

## ▪ FBRM (Focused Beam Reflectance Measurement)


- Crystallization Process Development



Chemtrix™ Platform  
Labtrix™ for R&D Scale  
Kilotrix™ for cGMP Kilolab Scale



Vapourtec™



## High-Throughput Screening

Screening for discovery of new polymorphs, pharmaceutical salts, solvates, co-crystals, etc.


Freeslate Junior HTS



## Characterization

Complete physicochemical characterization of APIs and advanced intermediates utilizing state-of-the-art instrumentation.



PXRD, SCXRD, DSC, TGA  
PSD (wet/dry/inline)  
SEM with EDS  
FT-IR  
Solid State NMR



## Process Development

Optimized crystallization and scale-up through crystal engineering and inline monitoring techniques.


Crystal 16 Solubility  
Metastable Zone Studies  
Particle Track FBRM



- **Method qualification and validation**
  - Phase appropriate
  - Forced Degradation Studies
  - Photostability Studies
  - QbD Method Development – FUSION software
- **Identification, Characterization & Qualifications**
  - Starting materials, intermediates, impurities & API's
- **In-Process Controls**
- **Fate of Impurities Study**
- **Reference Standard Preparation and Qualification**
- **Development of methods for pGTI's (ppm & ppb levels)**
  - GCMS
  - LCMS
- **Non-Chromophore API's and intermediates**
  - Evaporative Light Scattering (ELS)
  - Mass Spec
  - Flame ionisation detector (FID)
  - Electron capture detector (ECD)
  - Charged aerosol detection (CAD)
- **Method Transfers**




# DS I Bioprocess Development and Biomanufacturing




## Development and API production for human & veterinary use

- Prokaryotic and eukaryotic expression systems
- Production of high quality material for research, diagnostic purposes and of processing aids (e.g. cytokines used in the production of cell therapy products)
- cGMP manufacturing:
  - Recombinant proteins
  - Live bacteria, including spore formers and anaerobic bacteria that can be used as drugs or vaccine vehicles
- Stability testing (real time and accelerated)



Non GMP & GMP Biomanufacturing	Batch size
Disposable bioreactors	Up to 200 L
Roller bottles	Up to 200 units
Cell factories	Up to 6xCF40
Wave bags	Up to 50 L






## DP | Small Molecules development




- Strong expertise in **preformulation** and **formulation development** (Non GMP/GMP) for oral, topical and parenteral dosage forms including **placebos**
- Standard technologies such as granulation, fluid-bed granulation and coating, pan coating available in small scale
- Experience with BCS class II and IV compounds suffering from **low-solubility** (spraydrying, co-micronization, nano-milling, S(M)EDDS)
- Development of **lyophilization** cycles
- Accelerated Stability Assessment Program (**ASAP**)
- Adapted technologies (taste masking) & dosage forms (minitablets, orodispersible drugs, oral freeze-dried products) for good palatability
- Long experience in liquid formulation








# DP | Small Molecules Technologies and Applications



non-GMP and GMP	non-sterile						sterile		
	Tablets	Mini-Tablets Beads	Bilayer-Tablets	Capsules	Oral Solutions	Cremes, Gels	Vials	Prefilled Syringes	Cartridges
High Shear Granulation	■	■	■	■					
Fluid Bed Granulation	■	■	■	■					
Fluid Bed Coating		■		■					
Pan Coating	■		■	■					
Spraydrying	■	■	■	■					
Nano-Milling					■	■	■	■	
High Shear Mixing					■	■			
Lyophilisation						■	■	■	




# DP I Biologicals Formulation Development



non-GMP and GMP	Solid Formulations		Liquid Formulations	
	Spray drying	Lyophilisation	Solution	Emulsion
Proteins (Enzymes, mAb's)	Portfolio	Portfolio	Portfolio	Portfolio
Peptides	Portfolio	Portfolio	Portfolio	Portfolio
Vaccines	Portfolio	Portfolio	Capability	Portfolio
Bacteria (incl. Spore Formers)	Portfolio	Portfolio	Capability	Capability
DNA (oligo)	Portfolio	Portfolio	Portfolio	Portfolio
RNA	Portfolio	Portfolio	Capability	Capability
	solid formulations		liquid formulations	

 Portfolio  Capability

- Wide range of technologies & dosage forms
- Specific experience on colon-targeted formulations
- Large portfolio of biological analytical methods to support development




# DP | Analytical Support




Analytical Methods	Biophysical methods	Stability studies
<ul style="list-style-type: none"><li>• Chromatography (UHPLC) <i>RPC</i> <i>Ion-exchange</i> <i>Size-exclusion</i> <i>Affinity</i> <i>2D-LC</i> <i>RI and UV detection</i></li><li>• Osmolality</li><li>• Density</li><li>• Water content (KF)</li><li>• Water activity</li><li>• Dissolution testing (USPI, II and III)</li><li>• Hardness</li><li>• Disintegration</li><li>• GC</li><li>• HRMS (QTOF)</li></ul>	<ul style="list-style-type: none"><li>• Calorimetry (m)DSC</li><li>• Spectroscopic methods <i>FT-IR</i> <i>UV-VIS</i> <i>Fluorescence</i></li><li>• Dynamic light scattering</li><li>• Zeta-potential</li><li>• Viscosity</li><li>• Rheometry*</li><li>• Microflow imaging (part. matter analysis)</li><li>• Laser Diffraction (powder and liquid)</li><li>• SEM*</li><li>• Raman*</li><li>• XRD*</li><li>• Hot and freeze stage analysis</li><li>• Syringeability testing</li><li>• Morpho G3</li></ul>	<ul style="list-style-type: none"><li>• In use testing</li><li>• Excipient compatibility</li><li>• ASAP (predictive modelling)</li><li>• ICH</li><li>• Accelerated Stability</li><li>• Forced degradation</li><li>• Photostability studies</li></ul>

\* Outsourced to partners



# DP | Non Sterile GMP Manufacturing




## Key features

- Equipment adequately scaled for early clinical phases up to small commercial batches
- High yields, low drug substance loss




Technology	Batch size
Solutions, suspensions, emulsions	5 mL up to 50 L (200 L if no heating)
Semi-solids	5 g up to 50 kg
Tablets	100 up to 200,000 units
Capsules	100 up to 200,000 units





# DP | Sterile GMP Manufacturing



- Liquid & lyophilized drug products
- Small filling volumes from 0,5 mL and up to 50 mL (manual & automatic systems)
- Small size of bulk volume
- Low line loss, down to 15 mL


## Parenteral




### Authorizations for all DS

except sexual hormones, cephalosporin /  $\beta$ -Lactam


Bulk	From < 0,5L and up to 20L
Vials	Up to 5,000 units
Syringes - Cartridges	Up to 5,000 units
IV Bags	Bulk up to 20L



# DP | Clinical Trial Supply



- 30 years of experience in Clinical Trial Material (IMP, IVP, Medical Device)
- Global experience / Cold chain capacities
- Placebo development / Double-blind management
- QP Release of Drug Products
- Controlled drugs management



- **Primary & secondary packaging**

- Customized solutions for patient kits
- Randomization list & decoding envelopes
- Support on supply chain strategy
- Ancillaries supply & kits
- Web interface for shipment management
- Comparator supply, blinding & labeling
- Extension of expiry date

	<ul style="list-style-type: none"> <li>• 5 ISO7 suites</li> <li>• 3 ISO8 suites</li> </ul>
Secondary packaging	• 13 suites at RT and 2/8°C
Storage	• 700 m <sup>3</sup> ((25 000 ft <sup>3</sup> ))

- **QP services**

- GMP certification/Final batch release
- Site audits to support QP declaration/import, testing & certification and/or release of batches


- **GMP storage 15 - 25°C / 2 – 8°C / -20°C / - 80°C**

- **Distribution**



Corporate QP  
on site

# Orphan Drugs | Full Cycle Support



## ORPHAN DRUGS



**Short cycle from clinical to market**



**Small size commercial batches**


### **Our experience in Orphan Drugs (including pediatric):**

- Pharmaceutical development, manufacturing of clinical & commercial batches
- Regulatory support with preparation of quality files

**4** commercial products are routinely manufactured for EU and Japan markets

**25 +** developments and clinical batches production for rare diseases

# Let's Start!



**Fully integrated services enabling the most efficient pathway from preclinical candidate to late phase clinical product and commercialization.**

- Preclinical and early clinical development
- Clinical and small scale manufacturing (GMP)
- Clinical trial material (packaging & logistics)
- Global project management | CMC - RA

## Contact us!



[cdmo@eurofins.com](mailto:cdmo@eurofins.com)

[www.eurofins.com/cdm](http://www.eurofins.com/cdm)

